Literature DB >> 10639445

Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages.

L Y Armitige1, C Jagannath, A R Wanger, S J Norris.   

Abstract

The mechanism of pathogenesis of Mycobacterium tuberculosis is thought to be multifactorial. Among the putative virulence factors is the antigen 85 (Ag85) complex. This family of exported fibronectin-binding proteins consists of members Ag85A, Ag85B, and Ag85C and is most prominently represented by 85A and 85B. These proteins have recently been shown to possess mycolyl transferase activity and likely play a role in cell wall synthesis. The purpose of this study was to generate strains of M. tuberculosis deficient in expression of the principal members of this complex in order to determine their role in the pathogenesis of M. tuberculosis. Constructs of fbpA and fbpB disrupted with the kanamycin resistance marker OmegaKm and containing varying amounts of flanking gene and plasmid vector sequences were then introduced as linear fragments into H37Rv by electroporation. Southern blot and PCR analyses revealed disruption of the homologous gene locus in one fbpA::OmegaKm transformant and one fbpB::OmegaKm transformant. The fbpA::OmegaKm mutant, LAa1, resulted from a double-crossover integration event, whereas the fbpB::OmegaKm variant, LAb1, was the product of a single-crossover type event that resulted in insertion of both OmegaKm and plasmid sequences. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis confirmed that expression of the disrupted gene was not detectable in the fbpA and fbpB mutants. Analysis of growth rates demonstrated that the fbpB mutant LAb1 grew at a rate similar to that of the wild-type parent in enriched and nutrient-poor laboratory media as well as in human (THP-1) and mouse (J774.1A) macrophage-like cell lines. The fbpA mutant LAa1 grew similarly to the parent H37Rv in enriched laboratory media but exhibited little or no growth in nutrient-poor media and macrophage-like cell lines. The targeted disruption of two genes encoding mycolyl transferase and fibronectin-binding activities in M. tuberculosis will permit the systematic determination of their roles in the physiology and pathogenesis of this organism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639445      PMCID: PMC97204          DOI: 10.1128/IAI.68.2.767-778.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Efficient homologous recombination in fast-growing and slow-growing mycobacteria.

Authors:  A Baulard; L Kremer; C Locht
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

Review 2.  Characterization of the Mycobacterium tuberculosis phagosome.

Authors:  D L Clemens
Journal:  Trends Microbiol       Date:  1996-03       Impact factor: 17.079

3.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis.

Authors:  J T Belisle; V D Vissa; T Sievert; K Takayama; P J Brennan; G S Besra
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

4.  The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  J M Reyrat; F X Berthet; B Gicquel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

5.  Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis.

Authors:  G Harth; B Y Lee; J Wang; D L Clemens; M A Horwitz
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

6.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.

Authors:  K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; I M Orme; S Baldwin; C D'Souza; A Drowart; E Lozes; P Vandenbussche; J P Van Vooren; M A Liu; J B Ulmer
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

Review 7.  Molecular mechanisms of drug resistance in Mycobacterium tuberculosis.

Authors:  J S Blanchard
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

8.  Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides.

Authors:  A K Azad; T D Sirakova; L M Rogers; P E Kolattukudy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo.

Authors:  C Jagannath; H S Allaudeen; R L Hunter
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

10.  Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates.

Authors:  V Balasubramanian; M S Pavelka; S S Bardarov; J Martin; T R Weisbrod; R A McAdam; B R Bloom; W R Jacobs
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

View more
  82 in total

1.  Cyclipostins and cyclophostin analogs inhibit the antigen 85C from Mycobacterium tuberculosis both in vitro and in vivo.

Authors:  Albertus Viljoen; Matthias Richard; Phuong Chi Nguyen; Patrick Fourquet; Luc Camoin; Rishi R Paudal; Giri R Gnawali; Christopher D Spilling; Jean-François Cavalier; Stéphane Canaan; Mickael Blaise; Laurent Kremer
Journal:  J Biol Chem       Date:  2018-01-04       Impact factor: 5.157

2.  Inactivation of the Mycobacterium tuberculosis antigen 85 complex by covalent, allosteric inhibitors.

Authors:  Lorenza Favrot; Daniel H Lajiness; Donald R Ronning
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

Review 3.  Bacterial Virulence Factors: Secreted for Survival.

Authors:  Aditya Kumar Sharma; Neha Dhasmana; Neha Dubey; Nishant Kumar; Aakriti Gangwal; Meetu Gupta; Yogendra Singh
Journal:  Indian J Microbiol       Date:  2016-11-05       Impact factor: 2.461

4.  Biochemical Characterization of Isoniazid-resistant Mycobacterium tuberculosis: Can the Analysis of Clonal Strains Reveal Novel Targetable Pathways?

Authors:  Luisa Maria Nieto R; Carolina Mehaffy; M Nurul Islam; Bryna Fitzgerald; John Belisle; Jessica Prenni; Karen Dobos
Journal:  Mol Cell Proteomics       Date:  2018-05-29       Impact factor: 5.911

Review 5.  Virulence factors of the Mycobacterium tuberculosis complex.

Authors:  Marina A Forrellad; Laura I Klepp; Andrea Gioffré; Julia Sabio y García; Hector R Morbidoni; María de la Paz Santangelo; Angel A Cataldi; Fabiana Bigi
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

6.  A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice.

Authors:  Haniyeh Aghababa; Ashraf Mohabati Mobarez; Nima Khoramabadi; Mehrdad Behmanesh; Mehdi Mahdavi; Majid Tebianian; Mehdi Nejati
Journal:  Mol Biotechnol       Date:  2014-06       Impact factor: 2.695

7.  Genetics of Capsular Polysaccharides and Cell Envelope (Glyco)lipids.

Authors:  Mamadou Daffé; Dean C Crick; Mary Jackson
Journal:  Microbiol Spectr       Date:  2014

Review 8.  TB research at UT-Houston--a review of cord factor: new approaches to drugs, vaccines and the pathogenesis of tuberculosis.

Authors:  Robert L Hunter; Lisa Armitige; Chinnaswamy Jagannath; Jeffrey K Actor
Journal:  Tuberculosis (Edinb)       Date:  2009-12       Impact factor: 3.131

9.  Elastin, a novel extracellular matrix protein adhering to mycobacterial antigen 85 complex.

Authors:  Chih-Jung Kuo; Christopher P Ptak; Ching-Lin Hsieh; Bruce L Akey; Yung-Fu Chang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

10.  T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections.

Authors:  Pascal Launois; Annie Drowart; Eliane Bourreau; Pierre Couppie; Claire-Michèle Farber; Jean-Paul Van Vooren; Kris Huygen
Journal:  Clin Dev Immunol       Date:  2010-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.